Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Trial Profile

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Jun 2020 Results assessing the safety and immunogenicity of subunit recombinant herpes zoster vaccine (RZV) in lung transplant recipients (LTR) who are known to be at high risk for herpes zoster reactivation compared to other organ transplant recipients, were presented at the 2020 American Transplant Congress.
    • 24 Sep 2019 Planned End Date changed from 5 Mar 2020 to 1 Mar 2020.
    • 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top